You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.
-
Development and in vitro validation of therapy for mucopolysaccharidosis III
SBC: Phoenix Nest Inc. Topic: 105DESCRIPTION provided by applicant Sanfilippo disease mucopolysaccharidosis type III MPS III is a devastating neurodegenerative lysosomal storage disorder of childhood for which there is no cure or effective treatment available The fundamental cause of MPS III is an inherited mutation in one of the enzymes required to catabolize heparan sulfate HS a glycosaminoglycan which plays importa ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Picture Me Fit: Engaging Youth in Community-Based Prevention
SBC: Prevention Strategies, LLC Topic: 600DESCRIPTION provided by applicant Approximately one third of all U S adults and children are obese and at risk for a wide range of related chronic health conditions such as cardiovascular disease hypertension diabetes stroke osteoarthritis sleep apnea and certain types of cancer The Center for Disease Control and Prevention CDC and other expert resources recognize that although indivi ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Development of an Antigen Capture Assay for Babesia microti
SBC: Biopeptides, Corp Topic: NIAIDDESCRIPTION provided by applicant Babesia microti the primary etiologic agent of human babesiosis is a tick borne eukaryotic apicomplexan pathogen that is an increasing threat to the US public health Although B microti is primarily a tick borne pathogen it can be transmitted by transfusion of infected blood Despite the well recognized threat there is no FDA licensed test to screen donor ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Development of Peptide Antibiotic Nucleic Acids
SBC: NUBAD, LLC Topic: NIAIDDESCRIPTION provided by applicant One of the challenges of research in infectious diseases is to find ways to use the increasing knowledge of the mechanisms underlying disease transformation and progression to develop novel therapeutic strategies for diseases such as increasing menace of bacterial infections Targeting specific RNA such as rRNA which are involved in proliferation and survival ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Live-attenuated ETEC Anti-Diarrhea Vaccine Construction via Synthetic Biology
SBC: Codagenix Inc. Topic: NIAIDDESCRIPTION provided by applicant The development of vaccine to combat Enterotoxigenic E coli ETEC is vital given the pathogenandapos s global impact on million individuals annually however an entirely new non conventional approach is needed Field studies have suggested that inert antigen based vaccines to combat ETEC have andquot essentially no efficacyandquot Therefore a vaccin ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Development of Novel S. aureus Antibiotics with Reduced Resistance Susceptibility
SBC: NOVALEX THERAPEUTICS, INC. Topic: NIAIDDESCRIPTION provided by applicant Widespread antibiotic use has accelerated S aureus resistance to almost all marketed antibiotic classes including beta lactams fluoroquinolones macrolides aminoglycosides tetracyclines as well as the newer linezolid and daptomycin Methicillin resistant S aureus MRSA is an increasing public health threat with deaths from MRSA infections already compar ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Development of broad spectrum Hepatitis C Virus NS3/4A protease inhibitors
SBC: NOVALEX THERAPEUTICS, INC. Topic: NIAIDDESCRIPTION provided by applicant This is a collaborative proposal to develop inhibitors with reduced susceptibility to resistance and improved genotype spectrum of activity against the NS A protease of the Hepatitis C virus HCV Over three percent of the worldandapos s population is infected with the hepatitis C virus HCV Unfortunately the current best treatment is still quite challeng ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health